

Oncology Today with Dr Neil Love: Key Presentations on Gynecologic Cancers from the 2021 ASCO Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Based on results from the GARNET study, the anti-PD-1 inhibitor dostarlimab is approved for which of the following subgroups of patients with recurrent or advanced endometrial cancer?

 - a. Patients with mismatch repair (MMR)-deficient tumors only
 - b. Patients with MMR-proficient tumors only
 - c. Patients with either MMR-deficient or MMR-proficient tumors
2. In the Phase III PAOLA-1 trial, which of the following combination regimens was compared to bevacizumab alone as maintenance therapy for patients with advanced ovarian cancer who responded to front-line platinum-based chemotherapy with bevacizumab?

 - a. Rucaparib/bevacizumab
 - b. Olaparib/bevacizumab
 - c. Veliparib/cediranib
3. Which of the following agents is an antibody-drug conjugate that targets tissue factor and is being investigated in the Phase III InnovaTV 301 trial for patients with recurrent/metastatic cervical cancer?

 - a. Tisotumab vedotin
 - b. Mirvetuximab soravtansine
 - c. Brentuximab vedotin
 - d. Enfortumab vedotin
4. Which of the following receptor proteins is the target of the novel antibody-drug conjugate mirvetuximab soravtansine, being investigated for the treatment of ovarian cancer?

 - a. FGFR2b
 - b. HER2
 - c. Folate receptor-alpha